Enfusion Results Presentation Deck

Financial outlook Revenue Adjusted EBITDA *Adjusted EBITDA guidance excludes stock-based compensation of $12 million for the full year 2023. *:enfusion 2023E $185-$190 million $32-$34 million These statements are forward-looking and actual results may differ materially. Refer to the "Forward-Looking Statements" safe harbor section below for information on the factors that could cause our actual results to differ materially from these forward-looking statements. Enfusion has not reconciled its estimates for Adjusted EBITDA to net income under U.S. generally accepted accounting principles (GAAP) due to the uncertainty and potential variability of expenses that may be incurred in the future. Accordingly, a reconciliation is not available without unreasonable effort. PROPRIETARY AND CONFIDENTIAL Ⓒ2023 ENFUSION. ALL RIGHTS RESERVED. 13

View entire presentation